Exosomal MicroRNAs Released by Pediatric Cardiac Progenitor Cells

Xiaoyan Ke,Thomas Thum

DOI: https://doi.org/10.1161/circresaha.117.310443

IF: 23.213

2017-01-01

Circulation Research

Abstract:HomeCirculation ResearchVol. 120, No. 4Exosomal MicroRNAs Released by Pediatric Cardiac Progenitor Cells Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBExosomal MicroRNAs Released by Pediatric Cardiac Progenitor Cells Ke Xiao and Thomas Thum Ke XiaoKe Xiao From the Institute of Molecular and Translational Therapeutic Strategies (K.X., T.T.) and Excellence Cluster REBIRTH (T.T.), Hannover Medical School, Germany. and Thomas ThumThomas Thum From the Institute of Molecular and Translational Therapeutic Strategies (K.X., T.T.) and Excellence Cluster REBIRTH (T.T.), Hannover Medical School, Germany. Originally published17 Feb 2017https://doi.org/10.1161/CIRCRESAHA.117.310443Circulation Research. 2017;120:607–609Cell-based therapies have been intensively studied as promising treatments for the diseased heart, although the mechanisms underlying the modest beneficial effects to date are far from being clear. In this issue of Circulation Research, Agarwal et al1 suggest that both oxygen levels and age of donors are able to influence the beneficial effects of pediatric cardiac progenitor cell (CPC)–derived exosomes. In addition, the change of miRNA content in hypoxic/normoxic preconditioned exosomes from different age groups are found to be associated with differences in reparative effects in a rat model of ischemia–reperfusion injury based on a computational modeling approach. The authors found at day 3 after ischemia–reperfusion injury that exosomes derived from neonatal cells led to a significant improvement of ejection fraction (no matter pretreated by hypoxic condition or not), whereas hypoxic exosomes from infant- and child-derived CPCs showed improvement at day 28 after ischemia–reperfusion injury. Reduced fibrosis and increased angiogenesis in the infarcted region were observed after treatment with hypoxic exosomes from all age groups. To predict and further explore the underlying mechanisms, the authors took an unbiased multivariate modeling approach that they used before2 to establish a connection between donor age and oxygen content, miRNAs, and the functional consequences. A partial least squares regression model was created and tested for the capability of predicting miRNAs with functional relevance. To prove the predicted miRNAs derived from the partial least squares regression modeling approach, several angiogenesis-associated miRNAs without known related function were tested in vitro.Article, see p 701Numerous studies have suggested an improvement of cardiac function after delivery of cardiac stem cells including human CPC in animal models; however, the mechanisms behind the observed therapeutic effects are not fully elucidated. Paracrine signaling pathways play an essential role in the repair action via activation of the adjacent cells added to the intrinsic regeneration and differentiation capacity of the exogenous stem cells. Consistent with the hypothesis of a paracrine effect, functional improvement of infarcted rat hearts has been reported after administration of conditioned medium from stem cells in which multiple cytokines contribute to the elevated proliferation and decreased apoptosis.3 Besides soluble proteins such as cytokines and chemokines, stem cells also release various types of membrane vesicles into the extracellular space, including exosomes and microvesicles, both of which can function as mediators of intercellular communication.4 As a subgroup of small extracellular vesicles released by most cell types via exocytosis, exosomes can transport molecules, including proteins, DNAs, mRNAs, lncRNAs, and miRNAs from the cells of origin to the local or remote recipient cells. Also, the amount of exchanged exosomes and the content carried by them are highly regulated by the physiological and pathological state of the microenvironment.To explore the underlying mechanism by which the cardiac stem cell therapy improved the repair of injured myocardium, Ibrahim et al5 reported functional improvement in a mouse model of myocardial infarction by injection of exosomes released from cardiosphere-derived cells (CDC), whereas reduced benefits were observed after inhibiting the production of exosomes. In particular, their results suggest that miR-146a enriched in CDCs is able to replicate some benefits to a certain extent when administered alone. Likewise, preserved cardiac function has been found in a mouse myocardial infarction model after intramyocardial delivery of mouse embryonic fibroblast–derived exosomes with increased proliferation rate of cardiomyocyte and decreased fibrosis.6 The authors also emphasized a stem cell–specific microRNA, miR-294, which is a member of miR-290 family, to possess an important role in repair and preservation of cardiac function when transported by exosomes to recipient CPCs.In addition, a wide range of mechanisms and potentials has been suggested for exosomes and circulating miRNAs with growing amount of evidence from different aspects. For instance, enrichment of star miRNAs located in the exosome of cardiac fibroblast but not in the intracellular part of the same cell implicates a selective package mechanism of exosomes; among them, mir-21* derived from fibroblast exosomes triggers the hypertrophy of cardiomyocytes by silencing 2 target genes.7 In a research combining gene and cell therapy, overexpression of HIF-1 (hypoxia-inducible factor 1) in donor stem cells induced higher exosomal content of miRNAs including miR-126 and miR-210, whereas it did not change the amount of exosomes in the conditioned medium, and the exosomal protective effects against ischemic stress were blocked by cotransfection of antagomirs.8On the contrary, oxygen levels in the stem cell microenvironment largely affects the potentials of cell therapy in many aspects from cell differentiation to survival rate, with many experimental studies supporting paracrine signaling mediating the beneficial response to hypoxic stress.9 In addition to the earlier research focused on growth factors or cytokines released by CPCs in response to hypoxic conditions,10 recent studies demonstrate that extracellular exosomes facilitate the cardiac regeneration as well.5 Moreover, expression levels of a cardiac miRNA, miR-133a, has been reported to be largely elevated in the conditioned medium of CPC population by hypoxic stimuli.11Additionally, age has been reported as another crucial factor associated with the regenerative capacity of cardiomyocytes in mouse hearts12; however, the effects of donor age on cell-based therapy in cardiac disease, especially the underlying mechanisms, have not been studied intensively. A reason may be the fact that the cardiac miRNA content changes significantly during aging.13 Nevertheless, significantly higher regenerative ability of neonatal CDCs were observed in the rat infarct model when compared with the results from adult CDCs.14 Elevated cytokine secretion by neonatal CDCs are suggested to account for the increased angiogenic potential.Taken together, circulating extracellular exosomes and the packaged miRNAs are mediators involved in the intercellular communication between different types of cardiac cells including cardiac stem cells. Introducing the new theory that putative beneficial exosomes and the packed miRNAs secreted by exogenous stem cells take part in the cardioprotection leads to an alternative therapeutic strategy by delivery of cell-free molecules (eg, in exosomes or related (nano)particles).However, most researches mentioned above were performed on the basis of specific pathological/physiological models and focused on a few selected target molecules such as a set of miRNAs only, whereas the mechanism underlying those beneficial effects involves multiple factors. It might be more reasonable and profitable to use a system biology approach to incorporate the molecular, cellular, and animal experimental data derived from various approaches to fulfill the complete map.In previous work of the same group, Gray et al2 already presented improved reparative capacity of CPC-derived exosomes in a rat model of ischemia–reperfusion injury under hypoxic condition compared with cells grown under normoxic conditions. Differentially expressed exosomal miRNAs are suggested to be responsible for the observed biological changes because RISC (RNA-induced silencing complex) inhibition abolished the effect on tube formation of recipient endothelial cells. Agarwal et al15 compared the beneficial effects of CPC-derived exosomes from 3 age groups within pediatric patients in a rat heart failure model; among them, neonatal CPCs showed the best reparative potential on cardiac function. Both articles used exosomal miRNA expression data generated by microarray in a statistical procedure (principal component analysis) to identify the covariate signals (miRNAs) and next applied partial least squares regression to develop a specific cue-signal-response model (Figure) to identify that the putative miRNAs contribute to certain physiological responses.Download figureDownload PowerPointFigure. Schematic framework to develop a predictive cue-signal-response model. In this article, the authors used exosomal miRNA expression levels as signals; patient age groups and normoxic/hypoxic condition as cues; angiogenesis, ejection fraction (EF), and fibroblast outcomes after exosomes injection as responses.To further explore the cardioprotective potential of CPCs in both aspects (age and hypoxia) and the putative connection between them, Agarwal et al1 reported the different outcomes in vivo after delivery of CPC-derived exosomes from 3 pediatric age groups and evaluate the hypoxic impacts on each group of the cells. Based on the PCA results, there are less differences between neonatal exosomal microRNAs in response to hypoxic conditioning, which fit well to the experimental results that significant improvement of ejection fraction was observed by delivery of neonatal exosomes regardless of hypoxic/normoxic conditioning. Although the number of patient samples included in this research was limited (3 per group), miRNAs from same age group clustered slightly better than the hypoxic/normoxic conditions, implicating an age-dependent relationship.1,15Along with the improvement of high-throughput techniques such as next-generation sequencing to detect the differential expression levels of various molecules under distinct conditions, statistical and system biology approaches, such as computational modeling, can facilitate our understanding from the growing amount of data. In this article and by applying such system biology approaches, Agarwal et al1 suggest that in addition to hypoxia, donor age is another important factor affecting the reparative potential of CPC-derived exosomes. In spite of the overall accordance between the experimental evidence and the covariate exosomal miRNAs, some aspects should be further considered. The release of exosomes from cells and the packed cargo is highly dynamic, which can be largely influenced by multiple stimuli, such as calcium, cytokines, and hypoxic stress in the microenvironment. Moreover, miRNAs represent only a part of the content carried by exosomes; therefore, it is worthwhile to incorporate more signals, such as transcriptome and proteome data from exosomes, to optimize and improve the predictive ability of the model. On the contrary, to prove the reliability of this model, further functional experiments of the predicted miRNAs in vivo are needed.Sources of FundingDr Thum received funding from the IFB-Tx (BMBF 01EO1302), the REBIRTH Excellence Cluster, Fondation Leducq (MIRVAD), and the European Union funded ERC Grant LongHeart.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Thomas Thum, MD, PhD, Institute of Molecular and Translational Therapeutic Strategies, OE 8886, Hannover Medical School, Carl-Neuberg Strasse 1, 30625, Hannover, Germany. E-mail [email protected]References1. Agarwal U, George A, Bhutani S, Ghosh-Choudhary S, Maxwell JT, Brown ME, Mehta Y, Platt MO, Liang Y, Sahoo S, Davis ME.Experimental, systems, and computational approaches to understanding the microRNA-mediated reparative potential of cardiac progenitor cell–derived exosomes from pediatric patients.Circ Res. 2017; 120:701–712. doi: 10.1161/CIRCRESAHA.116.309935.LinkGoogle Scholar2. Gray WD, French KM, Ghosh-Choudhary S, Maxwell JT, Brown ME, Platt MO, Searles CD, Davis ME.Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology.Circ Res. 2015; 116:255–263. doi: 10.1161/CIRCRESAHA.116.304360.LinkGoogle Scholar3. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K.Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury.Am J Physiol Heart Circ Physiol. 2006; 291:H886–H893. doi: 10.1152/ajpheart.00142.2006.CrossrefMedlineGoogle Scholar4. Bang C, Thum T.Exosomes: new players in cell-cell communication.Int J Biochem Cell Biol. 2012; 44:2060–2064. doi: 10.1016/j.biocel.2012.08.007.CrossrefMedlineGoogle Scholar5. Ibrahim AG, Cheng K, Marbán E.Exosomes as critical agents of cardiac regeneration triggered by cell therapy.Stem Cell Reports. 2014; 2:606–619. doi: 10.1016/j.stemcr.2014.04.006.CrossrefMedlineGoogle Scholar6. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction.Circ Res. 2015; 117:52–64. doi: 10.1161/CIRCRESAHA.117.305990.LinkGoogle Scholar7. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy.J Clin Invest. 2014; 124:2136–2146. doi: 10.1172/JCI70577.CrossrefMedlineGoogle Scholar8. Ong SG, Lee WH, Huang M, Dey D, Kodo K, Sanchez-Freire V, Gold JD, Wu JC.Response to letter regarding article, “cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer”.Circulation. 2015; 131:e385. doi: 10.1161/CIRCULATIONAHA.114.014467.LinkGoogle Scholar9. Gnecchi M, Zhang Z, Ni A, Dzau VJ.Paracrine mechanisms in adult stem cell signaling and therapy.Circ Res. 2008; 103:1204–1219. doi: 10.1161/CIRCRESAHA.108.176826.LinkGoogle Scholar10. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G.Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression.Circ Res. 2009; 104:1209–1216. doi: 10.1161/CIRCRESAHA.109.197723.LinkGoogle Scholar11. Izarra A, Moscoso I, Levent E, Cañón S, Cerrada I, Díez-Juan A, Blanca V, Núñez-Gil IJ, Valiente I, Ruíz-Sauri A, Sepúlveda P, Tiburcy M, Zimmermann WH, Bernad A.miR-133a enhances the protective capacity of cardiac progenitors cells after myocardial infarction.Stem Cell Reports. 2014; 3:1029–1042. doi: 10.1016/j.stemcr.2014.10.010.CrossrefMedlineGoogle Scholar12. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA.Transient regenerative potential of the neonatal mouse heart.Science. 2011; 331:1078–1080. doi: 10.1126/science.1200708.CrossrefMedlineGoogle Scholar13. Gupta SK, Foinquinos A, Thum S, Remke J, Zimmer K, Bauters C, de Groote P, Boon RA, de Windt LJ, Preissl S, Hein L, Batkai S, Pinet F, Thum T.Preclinical development of a microRNA-based therapy for elderly patients with myocardial infarction.J Am Coll Cardiol. 2016; 68:1557–1571. doi: 10.1016/j.jacc.2016.07.739.CrossrefMedlineGoogle Scholar14. Simpson DL, Mishra R, Sharma S, Goh SK, Deshmukh S, Kaushal S.A strong regenerative ability of cardiac stem cells derived from neonatal hearts.Circulation. 2012; 126:S46–S53. doi: 10.1161/CIRCULATIONAHA.111.084699.LinkGoogle Scholar15. Agarwal U, Smith AW, French KM, et al. Age-dependent effect of pediatric cardiac progenitor cells after juvenile heart failure.Stem Cells Transl Med. 2016; 5:883–892. doi: 10.5966/sctm.2015-0241.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Zhang N, Zhu J, Ma Q, Zhao Y, Wang Y, Hu X, Chen J, Zhu W, Han Z and Yu H (2020) Exosomes derived from human umbilical cord MSCs rejuvenate aged MSCs and enhance their functions for myocardial repair, Stem Cell Research & Therapy, 10.1186/s13287-020-01782-9, 11:1, Online publication date: 1-Dec-2020. February 17, 2017Vol 120, Issue 4 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.117.310443PMID: 28209789 Originally publishedFebruary 17, 2017 Keywordschemokinesstem cellcytokinesapoptosisexosomesEditorialsPDF download Advertisement